Slides
Page 1
© 2026. Zai Lab. All Rights Reserved.NASDAQ:ZLAB | HKEX:9688 ESMO 2026 Zoci (ZL-1310): Backbone ADC in SCLC and NEC October 2026
Page 2
Forward-Looking Statements 2 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to our strategy and plans; potential of andexpectations for our business, commercial products, and pipeline programs; , including specifically zoci (ZL-1310), our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches and clinical stage products like zoci); the peak sales potential of our programs; capital allocation and investment strategy; clinical development programs and related clinical trials, including the planned initiation, design, and number of clinical trials, our plans for combination regimens with our collaboration partners; expected timing and results of clinical trial data, data readouts, and presentations; regulatory discussions, submissions, filings, and approvalsand the timing thereof, including expected timing of investigational new drug applications, the potential submission of our first biologics license application and potential global approvals; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; the potential market opportunities of, and estimated addressable markets for, our commercial products and product candidates, including estimated patient populations; and our future financial and operating results. All statements, other than statements of historical fact, included in this presentation are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “projected,” “target,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of U.S. federal securities laws. Forward-looking statements are not guarantees or assurances of future performance because there are inherent difficulties in predicting future results. Forward-looking statements are based on our expectations and assumptions as of the date of this presentation and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections described in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of clinical and pre-clinical development of our product candidates, including the risk that preliminary or interim data may not be predictive of final or later-stage results and that cross-trial comparisons may not be meaningful, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5)potential competition from products and product candidates of other pharmaceutical and biotechnology companies, (6) any inability of third parties on whom we rely, such as our licensors and collaboration partners, to successfully carry out their contractual duties or meet expected deadlines, (7) risks related to doing business in China, and (8) other factors discussed in our most recent annual and quarterly reports and current reports we have filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developmentswill cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Market and Industry Data Unless otherwise indicated, market and industry data contained in this presentation, including estimated addressable markets,patient populations, and potential market opportunities, are based on management’s estimates and research, as well as industry and general publications and research, surveys, and studiesconducted by third parties. We have not independently verified the accuracy or completeness of this information. Management’s estimates are derived from publicly available information, their knowledge of our industry, and their assumptions based on such information and knowledge. This data involves a number of assumptions and limitations, and the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors. Trademarks The trademarks and registered trademarks appearing in this presentation are the property of their respective holders.
Page 3
Today’s Speakers and Agenda 3 Introduction Rafael Amado, MD Zoci: Highlights from ESMO 2026 – 1L SCLC Pedro Rocha, MD, PhD, MSc Summary and Q&A Rafael Amado, MD Pedro Rocha, MD, PhD, MSc Rafael Amado, MD President, Head of Global Research and Development, Zai Lab Pedro Rocha, MD, PhD, MSc Thoracic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain
Page 4
Disclosure Information 4 Pedro Rocha, MD, PhD, MSc • Receipt of honoraria from: Abbott, Amgen, AstraZeneca, Daiichi Sankyo, Lilly, ThermoFisher. • Consulting or Advisory Role for: Daiichi Sankyo, IGES Pharma. • Travel and Accommodation Expenses from: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Kyowa Kyrin, MSD, PharmaMar, Roche, ThermoFisher
Page 5
A broadening global oncology and immunology pipeline with a steady cadence of data readouts 5 Note: SAD = single ascending dose; MAD = multiple ascending dose; AD = atopic dermatitis; SCLC = small cell lung cancer; epNEC = extrapulmonary neuroendocrine carcinomas. (1) Amgen sponsors and leads global Phase 1b study; Zai Lab supplies study drug. (2) BI sponsors and leads global Phase 1b/2 study; Zai Lab supplies study drug. Programs (Target) Indication IND- enabling Ph 1 PoC Reg/ Ph 3 Status / Next Update Zoci (DLL3 ADC) Zoci 2L+ SCLC ● Data (interim analysis) 2H’27 Zoci + PD-(L)1 1L SCLC ● Data presented at ESMO; Phase 3 in planning Zoci + tarlatamab (TCE)1 ± PD-L1 1L+ SCLC ● Phase 1b ongoing Zoci + obrixtamig (TCE)2 ± PD-L1 SCLC & epNEC ● Phase 1b/2 initiating in 2H’26 Zoci epNEC ● Data (registrational study) 1H’27 ZL-6201 (LRRC15 ADC) ZL-6201 Sarcoma and others ● Data (PoC) 1H’27 ZL-1222 (PD-1/IL-12) ZL-1222 Solid tumors ● Phase 1 initiating in 2027 ZL-1311 (MUC17/CD3 TCE) ZL-1311 Solid tumors ● Phase 1 initiating in 1H’27 ZL-6202 (undisclosed) ZL-6202 Solid tumors Candidate selection ZL-1223 (undisclosed) ZL-1223 Solid tumors Candidate selection ZL-1503 (IL-13/IL-31Rα) ZL-1503 Mod-to-Sev AD ● Data (SAD, healthy volunteers) Q4’26 Data (MAD, atopic dermatitis) 1H’27 ZL-1505 (undisclosed) ZL-1505 Immunology diseases Candidate selection OncologyImmunology
Page 6
Zoci: A next-generation ADC engineered for potency and tolerability Sources: (1):218; Liu LN, et al. Poster presented at: ELCC; March 22, 2024; Prague, Czech Republic. TMALIN = Tumor Microenvironment-Activable LINker-payload; (2) Sabari JK, et al. Nat Rev Clin Oncol. 2017;14(9):549‒61; (3) Saunders LR, et al. Sci Transl Med. 2015;7(302):302ra136; (4) Petrelli F, et al. Mol Clin Oncol. 2021;15 6 Zocilurtatug pelitecan, or zoci, is a novel ADC targeting DLL3, a neuroendocrine-specific antigen that is highly expressed in SCLC2-4 and validated as a therapeutic target A: Humanized anti-DLL3 IgG1 mAb B: Cleavable tripeptide-based linker C: Camptothecin derivative payload, C24 A B C Key Properties Zoci is built on the TMALIN® platform for potent, targeted tumor killing 1 DAR=8 Efficient payload delivery to targeted cells Potent Bystander Killing Topo-1 inhibitor payload C24 for maximum tumor impact, including heterogeneous tumors TME-Specific Release Minimizes systemic toxicity for better tolerability through tumor microenvironment-activable linker Structure and Mechanism of Action of ZL-1310
Page 7
Five attributes position zoci as a potential backbone ADC in SCLC and NEC 7 A differentiated clinical profile, a global Phase 3 underway and a broad development program in SCLC and NEC 01 High response rates 02 Durable responses 03 04 05 Leading global development Strong efficacy • Favorable tolerability • Intracranial activity • Global scale Robust brain activity Potential best-in-class safety
Page 8
© 2023. Zai Lab. All Rights Reserved.NASDAQ:ZLAB | HKEX:9688 DLL3 ADC Zoci (ZL-1310) ESMO 2026 Data Update Pedro Rocha, MD, PhD, MSc Vall d’Hebron University Hospital
Page 9
ZL-1310 (DLL3 ADC) plus atezolizumab ± carboplatin in Extensive-stage Small Cell Lung Cancer Zhao Jun, MD Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China 9
Page 10
Content of this presentation is copyrightand responsibility of the author. Permission is required for re-use. Jun Zhao1, Valentina Gambardella2, Wenxiu Yao3, Zhen Wang4, Pedro Rocha5, Jie Hu6, María Eugenia Olmedo García7, Qiming Wang8, David Vicente Baz9, Luis Paz-Ares10, Mariam Alexander11, Anne C. Chiang12, Manuel Cobo Dols13, Yingying Du14, Grace K. Dy15, Martin Gutierrez16, Alexander Spira17, Liza Villaruz18, Renke Zhou19, Yi-Long Wu3 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China; 2Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain; 3Sichuan Cancer Hospital, Chengdu, China; 4Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; 5Instituto de Investigacion Oncologica Vall d’Hebron (VHIO), Barcelona, Spain; 6Shanghai Geriatric Medical Center, Zhongshan Hospital, Fudan University, Shanghai, China; 7Hospital Universitario Ramón y Cajal, Madrid, Spain; 8Henan Cancer Hospital, Zhengzhou, China; 9Hospital Universitario Virgen Macarena, Sevilla, Spain; 10Hospital Universitario 12 de Octubre, Madrid, Spain; 11Medical University of South Carolina, Charleston, SC, USA; 12Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA; 13Hospital Regional Universitario de Málaga, Málaga, Spain; 14The First Affiliated Hospital of Anhui Medical University, Hefei, China; 15Roswell Park Comprehensive Cancer Center, Buffalo, NY , USA; 16Hackensack University Medical Center, Hackensack, NJ, USA; 17NEXT Oncology Virginia, Fairfax, VA, USA; 18UPMC Hillman Cancer Center, Pittsburgh, PA, USA; 19Zai Lab (US) LLC, Cambridge, USA 10
Page 11
Study Overview • Phase I, open-label, dose-escalation and expansion study of ZL-1310 as monotherapy and in combination with atezolizumab, with (triplet) or without (doublet) carboplatin in ES-SCLC (NCT06179069). • Efficacy and safety reported for 1L patients who had the opportunity of at least 12-week follow-up with data cutoff date of Sept 9, 2026. This report includes data from all 13 patients who received the triplet regimen as 1L treatment for ES-SCLC. Triplet ZL-1310 + atezolizumab 1200 mg + carboplatin as induction, followed by ZL-1310 + atezolizumab as maintenance, IV Q3W ZL-1310 0.8 mg/kg + atezolizumab + carboplatin 4 mg/ml/min ZL-1310 1.2 mg/kg + atezolizumab + carboplatin 4 mg/ml/minZL-1310 0.8 mg/kg + atezolizumab + carboplatin 5 mg/ml/min • Patient population • Doublet: • Dose escalation: relapsed / refractory ES-SCLC ≤2 prior lines of therapy. • Backfill: Newly diagnosed ES-SCLC (1L) or ES-SCLC completed standard 1L induction therapy and had not progressed (1L maintenance). • Expansion: Newly diagnosed ES- SCLC (1L) • Triplet: Newly diagnosed ES-SCLC (1L) • Asymptomatic brain metastasis (treated or untreated) allowed • Prior DLL3-targeted therapy allowed • ECOG Performance Status 0-1 Dose Escalation This report includes data from 43 1L ES-SCLC patients, including 33 treated with ZL-1310 at 1.6 mg/kg and 10 at 1.2 mg/kg. Doublet ZL-1310 + atezolizumab 1200 mg IV Q3W ZL-1310 0.8 mg/kg + atezolizumab (n=3） ZL-1310 1.2 mg/kg + atezolizumab (n=5) ZL-1310 1.6 mg/kg + atezolizumab (n=7) ….. Backfill ….. ….. + Expansion Q3W: once every 3 weeks; PS: Performance Status; RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1 11 ZL-1310-001 Study Schema (ZL-1310 plus atezolizumab ± carboplatin)
Page 12
12 Baseline Characteristics for 1L Patients Demographics and Baseline Characteristics for 1L Patients ZL-1310 + atezolizumab doublet ZL-1310 + atezolizumab + carboplatin triplet Dose Level Total Dose Level TotalZL-1310 ZL-1310 Carbo AUC5 Carbo AUC4 1.2 mg/kg (n=10) 1.6 mg/kg (n=33) Total (n=43) 0.8 mg/kg (n=4) 0.8 mg/kg (n=3) 1.2 mg/kg (n=6) Total (n=13) Male, n (%) 8 (80.0) 26 (78.8) 34 (79.1) 3 (75.0) 3 (100 ) 4 (66.7) 10 (76.9) Age, median (range), years 62 (51, 75) 63 (46, 75) 63 (46, 75) 61 (58, 66) 69 (66, 69) 68 (59, 75) 66 (58, 75) ECOG PS = 1, n (%) 7 (70.0) 25 (75.8) 32 (74.4) 3 (75.0) 3 (100) 5 (83.3) 11 (84.6) Race, n (%) Asian 10 (100) 30 (90.9) 40 (93.0) 3 ( 75.0) 2 ( 66.7) 2 ( 33.3) 7 (53.8) White 0 3 (9.1) 3 (7.0) 0 1 ( 33.3) 4 ( 66.7) 5 (38.5) Brain Metastasis-Yes, n (%) 2 (20.0) 6 (18.2) 8 (18.6) 1 ( 25.0) 0 2 ( 33.3) 3 ( 23.1) Stage IV disease at initial diagnosis, n (%) 8 (80.0) 25 (75.8) 33 (76.7) 3 (75.0) 2 (66.7) 5 (83.3) 10 (76.9) ZL-1310 + atezolizumab doublet: • At ZL-1310 1.6 mg/kg, 33 patients were enrolled; the first 15 in the back fill cohort had the opportunity for ≥6 months of follow-up, with a median follow-up of 10.0 months. • At ZL-1310 1.2 mg/kg, 10 patients were enrolled; all had ≥6 months follow-up, with a median follow-up of 12.6 months. ZL-1310 + atezolizumab + carboplatin triplet: • In the dose-escalation triplet cohorts, 13 patients were enrolled, with median follow-up of 11.8 months.
Page 13
• High overall response rates were observed in patients receiving ZL-1310 + atezolizumab as 1L therapy (ORR for all dose level: 81.4%). Results: Target Tumor Reduction of Doublet in 1L Target Tumor Reduction per RECIST v1.1 by Investigator Assessment -110 -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 → → → * → → → → → → * * → → → → → → → → → → → → → → → → → → → → → → * *BOR per RECIST v1.1 Confirmed PR SD PD ZL-1310 1.2 mg/kg + Atezolizumab (n=10） ZL-1310 1.6 mg/kg + Atezolizumab (n=31） → Treatment Ongoing * Brain Metastatic Best Percentage Change from Baseline in the Sum of the Diameters of Target Lesion (%) * * * * Patients without target lesions at baseline or evaluable post-baseline tumor assessments were not shown. As of the DCO, two patients reached EOT without disease progression before an evaluable post-baseline assessment was obtained. Tumor response ZL-1310 1.2 mg/kg + Atezo (N=10) ZL-1310 1.6 mg/kg + Atezo (N=33) Best overall response, n (%) CR 0 0 PR 8 (80.0) 27 (81.8) SD 2 (20.0) 2 (6.1) PD 0 2 (6.1) cORR, % (95% CI) 80.0 (44.4, 97.5) 81.8 (64.5, 93.0) Tabe 2. Best Overall Response per RECIST v1.1 by Investigator Assessment
Page 14
Results: Durability of Tumor Reduction with Doublet 14 • Responses occurred rapidly: 34/35 (97.1%) responders achieving their response at the first post-baseline tumor assessment. • The responses were durable. • In the 10 patients receiving ZL-1310 1.2 mg/kg + atezolizumab as 1L, mDoR was 8.3 (4.0, NA) months. • In the first 15 patients receiving ZL-1310 1.6 mg/kg + atezolizumab as 1L, mDoR is not reached after a median follow-up of 10.0 months. Durable Tumor Reduction Observed in Doublet Cohorts Percentage Change from Baseline in the Sum of the Diameters of Target Lesion (%) Months after Treatment Initiation Zoci 1.6 mg/kg + Atezolizumab (n=31） → Treatment Ongoing Overall Response per RECISTv1.1 PR SD PD Zoci 1.2 mg/kg + Atezolizumab (n=10） Zoci 1.2 mg/kg + Atezolizumab (n=10） Zoci 1.6 mg/kg + Atezolizumab (n=31） → Treatment Ongoing Overall Response per RECISTv1.1 PR SD PD 6-month PFS rate81.9% All 33 patients on 1.6 mg/kg doublet In the first 15 patients of 1.6mg/kg doublet in 1L: (median follow-up: 10 mo) 66.7% Have not yet experienced disease progression or death at DCO Median PFSNR NR = not reached Of patients still on treatment as of DCO (25/33) 75.8%
Page 15
• Patients receiving ZL-1310 in combination with atezolizumab and carboplatin as 1L therapy demonstrated a high overall response rate (ORR) of 92.3%. Results: Target Tumor Reduction of Triplet in 1L 15 * Patients without target lesions at baseline or evaluable post-baseline tumor assessments were not shown. As of the DCO, one patient in triplet cohort reached EOT without disease progression before an evaluable post- baseline assessment. Target Tumor Reduction per RECIST v1.1 by Investigator Assessment ZL-1310 0.8 mg/kg + Atezolizumab + Carboplatin AUC 5 (n=4) ZL-1310 0.8 mg/kg + Atezolizumab + Carboplatin AUC 4 (n=3) → Treatment Ongoing * Brain Metastatic ZL-1310 1.2 mg/kg + Atezolizumab + Carboplatin AUC 4 (n=5) -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 Best Percentage Change from Baseline in the Sum of the Diameters of Target Lesion (%) → → * → → → * → * → BOR per RECIST v1.1 Confirmed PR
Page 16
• Patients receiving ZL-1310 in combination with atezolizumab and carboplatin as 1L therapy demonstrated a high overall response rate (ORR) of 92.3%. • mPFS is 8.4 months (95% CI 3.7, NA) and mDoR is 7.7 months (2.6, NA). Results: Durability of Tumor Reduction with Triplet 16 Durable Tumor Reduction Observed in Triplet Cohort Months after Treatment Initiation -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 210 Overall Response per RECISTv1.1 PR PD Percentage Change from Baseline in the Sum of the Diameters of Target Lesion (%) → → → → → → ZL-1310 0.8 mg/kg + Atezolizumab + Carboplatin AUC 5 (n=4) ZL-1310 0.8 mg/kg + Atezolizumab + Carboplatin AUC 4 (n=3) → Treatment OngoingZL-1310 1.2 mg/kg + Atezolizumab + Carboplatin AUC 4 (n=5)
Page 17
Results: Safety of Doublet as 1L Therapy 17 ZL-1310 plus atezolizumab is well tolerated. • No DLTs were observed in the dose escalation phase. • The majority of AEs were Grade 1 or 2, and non-serious. • Grade ≥3 AEs related to ZL-1310 occurred in 7/43 (16.3%) of patients, and SAEs related to ZL-1310 occurred in 5/43 (11.6%) of patients. • AE rate related to ZL-1310 that led to dose reduction (4.7%, 2/43) or discontinuation (1/43, 2.3%) was low. • No treatment-related deaths were reported. AEs, n (%) ZL-1310 1.2 mg/kg + Atezolizumab (N=10) ZL-1310 1.6 mg/kg + Atezolizumab (N=33) Total (N=43) Any 10 (100) 32 (97.0) 42 (97.7) Related to ZL-1310 10 (100) 31 (93.9) 41 (95.3) Serious 4 (40.0) 6 (18.2) 10 (23.3) Related to ZL-1310 2 (20.0) 3 (9.1) 5 (11.6) Grade ≥ 3 5 (50.0) 7 (21.2) 12 (27.9) Related to ZL-1310 4 (40.0) 3 (9.1) 7 (16.3) Leading to ZL-1310 Drug Interruption (1) 5 (50.0) 9 (27.3) 14 (32.6) Related to ZL-1310 4 (40.0) 5 (15.2) 9 (20.9) Leading to ZL-1310 Dose Reduction 0 2 (6.1) 2 (4.7) Related to ZL-1310 0 2 (6.1) 2 (4.7) Leading to ZL-1310 Drug Discontinuation 1 (10.0) 0 1 (2.3) Related to ZL-1310 1 (10.0) 0 1 (2.3) * As dose expansion of ZL-1310 + atezolizumab was ongoing at the data cutoff, safety data remain preliminary and subject to ongoing data cleaning. (1) Drug interruption includes infusion interruption or treatment delay compared with the scheduled date due to AE. Summary of Adverse Events - Doublet Combination Safety Analysis Set
Page 18
Results: Safety of Triplet as 1L Therapy 18 Compared with the doublet, the triplet was associated with increased hematologic toxicity, more frequent Grade ≥3 AEs, and a higher rate of dose interruptions. Although MTD was not met, the ZL-1310 dose was not escalated above 1.2 mg/kg. • A single DLT, Grade 4 thrombocytopenia, was observed in ZL-1310 0.8 mg/kg + Atezolizumab + Carboplatin AUC 5. No DLTs occurred in the ZL-1310 + Atezolizumab +Carboplatin AUC4 cohorts. • Grade ≥3 AEs related to ZL-1310 occurred in 7/13 (53.8%) of participants, and SAEs related to ZL-1310 occurred in 3/13 (23.1%). • One patient from ZL-1310 1.2 mg/kg + Atezolizumab + Carboplatin AUC 4 cohort had over-dose of Carboplatin and treatment-related death due to a G5 Sepsis. AEs, n (%) ZL-1310 0.8 mg/kg + Atezolizumab + Carboplatin AUC 5 (N=4) ZL-1310 0.8 mg/kg + Atezolizumab + Carboplatin AUC 4 (N=3) ZL-1310 1.2 mg/kg + Atezolizumab + Carboplatin AUC 4 (N=6) Total (N=13) Any 4 (100) 3 (100) 6 (100) 13 (100) Related to ZL-1310 3 (75.0) 2 (66.7) 5 (83.3) 10 (76.9) Serious 2 (50.0) 0 5 (83.3) 7 (53.8) Related to ZL-1310 1 (25.0) 0 2 (33.3) 3 (23.1) Grade ≥ 3 3 (75.0) 1 (33.3) 6 (100) 10 (76.9) Related to ZL-1310 2 (50.0) 1 (33.3) 4 (66.7) 7 (53.8) Leading to ZL-1310 Drug Interruption(1) 4 (100) 3 (100) 4 (66.7) 11 (84.6) Related to ZL-1310 3 (75.0) 2 (66.7) 4 (66.7) 9 (69.2) Leading to ZL-1310 Dose Reduction 0 0 1 (16.7) 1 (7.7) Related to ZL-1310 0 0 1 (16.7) 1 (7.7) Leading to ZL-1310 Drug Discontinuation 0 0 1 (16.7) 1 (7.7) Related to ZL-1310 0 0 1 (16.7) 1 (7.7) Summary of Adverse Events - Triplet Combination Safety Analysis Set (1) Drug interruption includes infusion interruption or treatment delay compared with the scheduled date due to AE.
Page 19
Common AEs related to ZL-1310 and ILD/pneumonitis Common ZL-1310 Related AE: • Doublet: The most common AEs related to ZL-1310 of all grades (≥20%) were anaemia (48.8%), nausea (39.5%), leukopenia* (34.9%), decreased appetite (30.2%), ALT increased, neutropenia* (27.9% each), hypertriglyceridaemia and lymphopenia* (23.3% each) • Triplet: The most common AEs related to ZL-1310 of all grades (≥20%) were anaemia and neutropenia* (61.5% each), thrombocytopenia* (53.8%), nausea (46.2%), ALT increased, decreased appetite, and leukopenia* (38.5% each), AST increased, constipation, malaise, and vomiting (30.8% each), and alopecia, hyperuricaemia, and hypoaesthesia (23.1% each). ILD / pneumonitis • ILD / pneumonitis was low in both regimens: 2/43 (4.7%) in doublet, and 2/13 (15.4%) in triplet, all Grade 1. Only one was reported so far in patients receiving ZL-1310 1.6 mg/kg and atezolizumab as 1L treatment (1/33, 3.0%). Leukopenia* includes AEs coded as Leukopenia and White blood cell count decreased. Neutropenia* includes AEs coded as Neutropenia and Neutrophil count decreased. Lymphopenia* includes AEs coded as Lymphocyte count decreased. Thrombocytopenia* includes AEs coded as Platelet count decreased and Thrombocytopenia. Common TRAEs related to ZL-1310 by grade (≥20%)
Page 20
• ZL-1310 1.6 mg/kg and atezolizumab doublet combination demonstrated high response rate (81.8%) and durable response as 1L treatment in ES-SCLC (median PFS for the first 15 patients who had 10-month follow-up not yet obtained). • ZL-1310 1.6 mg/kg and atezolizumab doublet combination is well tolerated. The overall AE rate, Grade 3 and above AE rate, SAE rate with this regimen is not higher than that of ZL-1310 1.6 mg/kg monotherapy as previously reported. Only a G1 ILD / pneumonitis was reported so far in patients receiving ZL-1310 1.6 mg/kg and atezolizumab as 1L treatment (1/33, 3.0%). • ZL-1310 1.6 mg/kg and atezolizumab doublet combination has more favorable risk / benefit profile compared to ZL - 1310 + atezolizumab + carboplatin triplet regimen. • A Phase III randomized 1L study will be started to further evaluate the combination regimen in ES-SCLC (NCT07796100). Conclusion 20
Page 21
© 2023. Zai Lab. All Rights Reserved.NASDAQ:ZLAB | HKEX:9688 Summary Rafael Amado, MD President, Head of Global R&D
Page 22
1L SCLC treatment landscape is evolving and zoci is strategically well positioned Sources: (1) Horn, NEJM 2018 (IMpower133); Paz-Ares, Lancet 2019 (CASPIAN). Grade 3/4 AEs for IO + chemo: IMpower133 56.6%, CASPIAN 62% (all-cause). 22 1 TODAY’S SOC IO + platinum/etoposide ± lurbi maintenance 2 WHERE SOC IS HEADING Tarla maintenance after induction 3 FUTURE OPPORTUNITY Upfront continuous treatment Conceptual vision Induction IO + platinum/etoposide (4 cycles) Maintenance IO IO + Platinum/ etoposide + lurbi + IO maintenance for eligible non-progressors Published benchmarks1 IO + chemo (IMpower133 / CASPIAN): ORR: 60–68% mPFS: 5.1–5.2 mo mOS: 12.3–12.9 mo Grade 3/4 AEs: ~57–62% Induction durvalumab + platinum/etoposide (4 cycles) Maintenance tarla + durvalumab Durvalumab + Platinum/ etoposide Key limitations / friction Some patients progress before maintenance (20-30% patients progressed during induction)1 Access, site readiness and patient preference may limit uptake zoci + IO + TCE Treat continuously until progression No separate induction / maintenance phases Potential strategic benefits Reach patients earlier Avoids attrition between induction and maintenance Chemotherapy-sparing, continuous regimen Positions zoci as a backbone ADC for next- generation combinations TCE-related CRS / neurotoxicity monitoring TRIPLET + DOUBLET Durvalumab + Tarla (TCE) + for eligible non-progressors
Page 23
⚫ Amgen and BI to sponsor and lead global Phase 1b and 1b/2 studies, respectively;Zai Lab will supply study drug ⚫ Zai Lab continues to pursue additional combination approaches Zoci + DLL3 TCE: Two global studies building toward 1L triplet in SCLC and NEC Dose exploration Dose expansion 1L ES-SCLC triplet S T AG E Zoci + IMDELLTRA® (tarlatamab) DeLLphi-313 · Global Phase 1b · patients with ES-SCLC Part 1 2L+ SCLC Zoci (multiple doses) + tarlatamab Part 2 2L / 2L+ SCLC Zoci (RP2D) + tarlatamab Part 3 1L ES-SCLC Zoci (RP2D) + tarlatamab + durvalumab Zoci + obrixtamig Global Phase 1b/2 · patients with poorly differentiated NEC Part 1 Poorly differentiated NECs Zoci (multiple doses) + obrixtamig Part 2 1L ES-SCLC Zoci (RP2D) + obrixtamig + atezolizumab Amgen 23
Page 24
Advancing zoci across multiple indications and treatment settings 24 Indication Line Regimen Phase Development Status ES-SCLC 2L+ Zoci monotherapy Phase 3 Phase 3 ongoing 1L Zoci + PD-L1 Phase 1 Phase 1 ongoing; Phase 3 in planning 1L+ Zoci + TCE ± PD-L1 Phase 1b Phase 1b ongoing epNEC 2L+ Zoci monotherapy Phase 1/2 Registrational cohort fully enrolled 1L+ Zoci + TCE ± PD-L1 Phase 1b/2 Phase 1b/2 initiating Other exploratory indications: LS-SCLC, brain tumor, LCNEC
Page 25
Zoci: 1L SCLC Data at ESMO Additional expansion opportunities for zoci and ZL-1503 3 Pivotal Trials by YE’26 for zoci 1H 2027 2H 2027 2028+2H’26 TODAY YE’26 ZL-1503: AD SAD data in healthy volunteers 2L+ SCLC 1L SCLC 2L+ NEC Zoci: Potential BLA submission A steady cadence of data readouts and regulatory submissions, with further expansion opportunities ahead Zoci: NEC Registrational topline data ZL-1503: AD MAD data in AD patients Note: SAD = single ascending dose; MAD = multiple ascending dose; AD = atopic dermatitis; SCLC = small cell lung cancer; epNEC = extrapulmonary neuroendocrine carcinomas Potential Global Approvals Zoci in 2L+ SCLC Zoci in 2L+ epNEC Zoci (+ IO) in 1L SCLC Zoci (+ TCE + IO) in 1L SCLC ZL-1503 in atopic dermatitis 25 Zoci: 2L+ SCLC (DLLEVATE) Registrational topline data
Page 26
© 2023. Zai Lab. All Rights Reserved.NASDAQ:ZLAB | HKEX:9688 Q&A
Page 27
© 2023. Zai Lab. All Rights Reserved.NASDAQ:ZLAB | HKEX:9688 APPENDIX
Page 28
Abbreviations 28 BLA Biologics License Application CAF Cancer-associated fibroblast CR Complete response DAR Drug-to-antibody ratio DLL3 Delta-like ligand 3 DoR Duration of response EP Etoposide and platinum epNEC Extrapulmonary neuroendocrine carcinoma ES-SCLC Extensive-stage small cell lung cancer GC Gastric cancer GEJ Gastroesophageal junction Ig Immunoglobulin IgAN Immunoglobulin A nephropathy ILD Interstitial lung disease IO Immuno-oncology LCNEC Large cell neuroendocrine carcinoma LRRC15 Leucine-rich repeat-containing protein 15 LS-SCLC Limited-stage small cell lung cancer mAb Monoclonal antibody MAD Multiple ascending dose MOA Mechanism of action NEC Neuroendocrine carcinoma OMG Ocular myasthenia gravis ORR Objective response rate pMN Primary membranous nephropathy PS Performance status Q3W Once every 3 weeks SAD Single ascending dose SCLC Small cell lung cancer TME Tumor microenvironment TRAE Treatment-related adverse event